SHACHAR PELES M.D. NPI 1568412930

NPI Details

Shachar Peles, M.D. is a medical oncology internal medicine in Palm Springs, FL with 28 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Shachar Peles, M.D. NPI is 1568412930. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4801 S CONGRESS AVE STE 400
PALM SPRINGS, FL
ZIP 33461-746
Phone: (561) 366-4100
Fax: (561) 366-4192

The NPI 1568412930 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Protein measurement, serum (HCPCS:84165)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Magnesium level (HCPCS:83735)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Folic acid level, serum (HCPCS:82746)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Injection of drug or substance into vein (HCPCS:96374)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Uric acid level, blood (HCPCS:84550)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Vitamin d-3 level (HCPCS:82306)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Phosphate level (HCPCS:84100)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Erythropoietin (protein) level (HCPCS:82668)
• Thyroid hormone, t3 measurement, free (HCPCS:84481)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Automated urinalysis test (HCPCS:81003)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Testosterone (hormone) level, total (HCPCS:84403)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Ct scan of chest with contrast (HCPCS:71260)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Drawing of blood for a medical problem (HCPCS:99195)
• Ultrasound of heart with color-depicted blood flow, rate, direction and valve function (HCPCS:93306)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Hemoglobin a1c level (HCPCS:83036)

The enumeration date for this NPI number is 5/10/2006 and was last updated on 8/12/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.